This guidance was written prior to the February 27, 1997 implementation of FDA's Good Guidance Practices, GGP's. It does not create or confer rights for or on any person and does not operate to bind FDA or the public. An alternative approach may be used if such approach satisfies the requirements of the applicable statute, regulations, or both. This guidance will be updated in the next revision to include the standard elements of GGP's.
## MASTER FILES

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction to Master Files for Devices (MAFs)</td>
<td>III-1</td>
</tr>
<tr>
<td>Definitions</td>
<td>III-2</td>
</tr>
<tr>
<td>Types of MAPs and Their Functions</td>
<td>III-2</td>
</tr>
<tr>
<td>The Format and Arrangement of an MAF</td>
<td>III-3</td>
</tr>
<tr>
<td>The Content of an MAF</td>
<td>III-4</td>
</tr>
<tr>
<td>Amending an MAF</td>
<td>III-4</td>
</tr>
<tr>
<td>Authorization to an MAF</td>
<td>III-5</td>
</tr>
<tr>
<td>Good Manufacturing Practice Regulations for Medical Devices</td>
<td>III-6</td>
</tr>
<tr>
<td>Representing an MAF</td>
<td>III-6</td>
</tr>
<tr>
<td>Where to Submit an MAF</td>
<td>III-6</td>
</tr>
<tr>
<td>Freedom of Information Act and an MAF</td>
<td>III-6</td>
</tr>
<tr>
<td>CDRH Contact Office for Assistance</td>
<td>III-7</td>
</tr>
</tbody>
</table>

### Introduction to Master Files for Devices (MAFs)

A premarket approval application (PMA) or an investigational device exemption application (IDE) usually contains data and other information that the applicant has developed and regards as trade secret or confidential commercial/financial information. Often the applicant needs to use another party's product (e.g., ingredient, subassembly, or accessory) or facility in the manufacture of the device. In order that a sound scientific evaluation may be made of the PMA, IDE, or other device submission, the review of data and other information related to the other party's product, facility, or manufacturing procedures is required. The other party, while willing to allow FDA's confidential review of this information, may not want the IDE or PMA applicant to have direct access to the information. To help preserve the trade secrets of the ancillary medical device industry and at the same time facilitate the sound scientific evaluation of medical devices, FDA established the device master file system.

This guideline only applies to the master files (MAFs) submitted to the Center for Devices and Radiological Health (CDRH). Master files in support of other products regulated by FDA, even though they may contain information previously submitted in an MAF, are to be submitted to the appropriate FDA center(s). The content and the way the master file is used may vary among FDA centers.

Other master files submitted for review in support of documents filed with FDA are:

- Biologics Master Files supporting Notices of Claimed Investigational Exemption for a New Drug (INDs) for biologies and biologic licenses.
- Drug Master Files (DMFs) supporting Investigational New Drug Applications (INDs), New Drug Applications (NDAs), and Abbreviated New Drug Applications (ANDAs).
- Food Master Files (PMFs) supporting Food Additive and Color Additive Petitions.
- Veterinary Medicine Master Files supporting Investigational New Animal Exemptions (INADs) and New Animal Drug Applications (NADAs).
The following list identifies the appropriate offices to which these master files are to be submitted and from which information can be obtained:

**Biologics Master Files**
- Div. of Biological Investigation New Drugs
- Food and Drug Administration (HFN-823)
- 5600 Fishers Lane
- Rockville, MD 20857
- Telephone: (301) 443-4864

**Drug Master Files**
- Div. of Drug Information Resources
- Food and Drug Administration (HFN-84)
- 5600 Fishers Lane
- Rockville, MD 20857
- Telephone: (301) 443-3910

**Food Master Files**
- Div. of Food and Color Additives
- Food and Drug Administration (HFF-330)
- 200 C Street, S.W.
- Washington, D.C. 20204
- Telephone: (202) 472-5676

**Veterinary Medicine Master Files**
- Document Control Section
- Food and Drug Administration (HFV-16)
- 5600 Fishers Lane
- Rockville, MD 20857
- Telephone: (301) 443-1567

**Definitions**

The following are commonly used terms relating to MAFs for devices and the documents referring to them:

- An "MAF holder" is an organization or person filing an MAF.
- An "applicant" is an organization or person filing a PMA.
- A "sponsor" is an organization or person filing an IDE.
- An "agent or representative for an MAF holder" is a person or organization authorized to represent the MAF holder before FDA concerning the contents of the MAF.

**Types of MAFs and Their Functions**

MAFs are only accepted from those organizations or persons who have not submitted or will not directly submit the information in a PMA, IDE, premarket notification (510(k)) or other device-related submission to FDA. MAFs may be submitted for various functions. These functions have been grouped by the following types:

- facilities and manufacturing procedures and controls;
- synthesis, formulation, purification and specifications for chemicals, materials (e.g., an alloy, plastic, etc.) or subassemblies for a device;
- packaging materials;
- contract packaging and other manufacturing (e.g., sterilization);
- nonclinical study data; and
- clinical study data.
The Format and Arrangement of an MAF

An MAF is a working document retained in the PMA Document Mail Center until referred to in a PMA, IDE, or other type of submission. To assure its convenient use, maintenance and storage, CDRH has established the following suggestions for its format and arrangement.

• Submit two complete and identical paper copies. In lieu of two paper copies, CDRH will accept one paper copy and a copy on microfiche.

• If paper, collate both copies.

• Number each volume and each page within each volume.

Standard page dimensions for FDA files. Measurements are in inches.
• In the first volume of each copy include a signed and dated cover letter identifying the submission as a device master file (MAF) and briefly describe the subject of the submission.

• U.S. standard size and weight bond paper (8½ inches × 11 inches) is preferred. Page sizes should not exceed 11 inches in length and 8½ inches in width.

• FDA’s system for storing MAFs requires that the volume be bound on the left side of the page using the U.S. standard size loose leaf page.

• Should it be necessary to use individual pages larger than the U.S. standard page size to present a floor diagram, device design, electrical diagram, etc., those pages should be mounted to allow the page to be opened for review and folded without damage when the volume is shelved.

• Allow a left margin of at least 3/4 inch to assure that the text is clear of binding.

• Individual volumes should not exceed 2 inches in thickness.

• DO NOT BIND volumes in book form or with plastic or metal spirals.

The Content of an MAF

A submission will not be accepted as an MAF if it is not substantive in nature and does not contain information that may reasonably be regarded as trade secret or confidential commercial or financial information.

The submission must include a cover letter, preferably bearing company letterhead, signed by a responsible official (e.g., Director of Regulatory Affairs or another manager). The letter should identify the submission as an MAF, and a contact person at the company or designated agent should be listed.

An MAF must be in the English language or be accompanied by accurate English translations of any of the documents that are in a language other than English.

Amending an MAF

After submission of an MAF, its information may need to be updated as a result of additional testing, additional applications of the MAF information or modification of the product that is the subject of the MAF.

Changes made in product or manufacturing operations can affect a client’s medical device and possibly result in the client marketing a device differing from that originally approved by FDA. This can also have an effect on product liability obligations and a client’s compliance with applicable FDA laws and regulations. It is, therefore, necessary to notify a client before proposed changes are made in your operations or product.
Authorization to an MAF

Information in an MAF may be incorporated by reference in a client's PMA, IDE, or other submissions to FDA. Their use of information in an MAF can only be authorized by the MAF holder or by a designated agent if so authorized. This authorization must be on company letterhead or that of the agent or representative. After FDA has referred to an MAF and the client's application has been approved, authorization cannot be withdrawn.

An MAF holder should provide a letter of authorization directly to a client with instructions that: (1) the original of the authorization letter be included in the original copy of the client's submission and (2) a copy be placed in each subsequent copy of the client's submission. An authorization letter should not be sent directly to CDRH for inclusion in the MAF or the client's submission.

Below is the format for a sample authorization letter.

[Use company letterhead stationery giving company name, address, and telephone number.]

[Date]

[Client's name]
[Mailing address including City, State and Zip Code]

Dear [Person responsible for filing the client's application]:

This letter authorizes the Food and Drug Administration to include by reference information in our device master file, MAF # [specify the correct MAF number] for [specify the subject of the MAF, e.g., PMA, IDE or 510(k)] in [specify the client's device by generic or trade name]. [You may add further restricting wording if you desire].

Sincerely yours,

[Name and title of the person responsible for MAF authorizations]
Good Manufacturing Practice Regulations for Medical Devices

Organizations or persons who submit IDEs, PMAs, or other device-related submissions to FDA may utilize contract manufacturers, sterilizers, packagers, etc. in the manufacture of their devices. The latter, for trade secret or confidentiality purposes, may submit a description of its facilities, manufacturing procedures and processes, and quality control procedures in an MAF rather than provide this information directly to the client for inclusion in its submission.

In its evaluation of the client’s submission, FDA may inspect the MAF holder’s facilities and manufacturing operations. When the MAF holder’s operation is subject to the Good Manufacturing Practice (GMP) regulations for medical devices (21 CFR 820), the MAF must address all appropriate GMP requirements applicable to the MAF holder’s operation. A client’s submission may be adversely affected if the MAF is incomplete or inaccurate. This is especially true in the case of a PMA because of the statutory requirement that a PMA contain a full description of the methods used in, and the facilities and controls used for, the manufacture, processing, and when relevant, packing and installation of the device.

Representing an MAF

If an MAF submitter is a foreign company, FDA recommends that it retain an agent or representative in the United States. This will usually facilitate any clarification or correction of deficiencies in the MAF information. Identify any agent by name, address, and telephone number and specify any limitations in the authority of the agent or representative. If limitations are not specified, FDA will assume that all information in the MAF may be discussed with the agent or representative. A designated agent or representative can be added or removed only by amending the MAF.

Where to Submit an MAF

An MAF and all amendments should be submitted to:

Food and Drug Administration
Center for Devices and Radiological Health
PMA Document Mail Center (HFZ-401)
1390 Piccard Drive
Rockville, MD 20850

SPECIAL NOTE: FDA will not pay any shipping or C.O.D. charges for incoming submissions or pick-up MAFs from the carrier. It is the submitter’s responsibility to assure prepaid delivery to the above address.

Receipt will be acknowledged by letter of all new MAF submissions. FDA’s acknowledgment letter of the original MAF will include the FDA assigned MAF reference number which must be included in all amendments to the MAF.

Freedom of Information Act and an MAF

Under the Freedom of Information Act (FOI), information in 510(k)s, IDEs, PMAs and other device-related submissions is subject to public disclosure unless determined by FDA to be trade secret or confidential commercial or financial information within the

III-6
meaning of 21 CFR 20.61 or otherwise prohibited from public disclosure. In the case of PMAs, FDA is required to make publicly available a detailed summary of safety and effectiveness information which is the basis for the FDA decision to approve, or deny approval of, the PMA. Information in such summaries cannot be used to establish the safety or effectiveness for another device by any person other than the one who submitted the information.

FOI public disclosure provisions apply whether or not the information in the 510(k), IDE, PMA, or other device-related submission was submitted by the applicant or is included by authorized reference to an MAF.

MAF holders should identify information in their MAFs which they consider to be trade secret or confidential commercial/financial information within the meaning of 21 CFR 20.61. MAF information already in the public domain is subject to disclosure (e.g., any published literature, catalog, or product specification sheets distributed by the MAF holder to potential customers).

CDRH Contact Office for Assistance

Procedural and other questions regarding MAFs should be directed to:

Food and Drug Administration
Center for Devices and Radiological Health
Premarket Approval Staff (HFZ-402)
1390 Piccard Drive
Rockville, MD 20850
Telephone (301)427-1188

Additional copies of the MAF Guideline are available from the above office and the CDRH Division of Small Manufacturers Assistance. Telephone requests will be accepted by the latter office by calling (800)638-2041 or (301)443-6597.